Barrett Esophagus
Conditions
Brief summary
To evaluate the efficacy and safety of the CryoBalloon Focal Ablation System for the treatment of previously-untreated (treatment naïve) Barrett's Esophagus (BE)
Detailed description
Coldplay III is a multi-center, prospective study that will provide evidence of the efficacy and safety of the System in treatment of patients with previously untreated (treatment naïve) low grade dysplasia (LGD) or high grade dysplasia (HGD) BE. Subjects may have a maximum of five (5) ablation treatment sessions during their 12 months of study participation to achieve complete eradication of their dysplastic BE and intestinal metaplasia. As many ablations as needed to treat the dysplastic areas are allowed in each treatment session at the discretion of the investigator.
Interventions
CryoBalloon Ablation System, a balloon-based cryotherapy device, provides controlled ablation for the treatment of BE. Deployed through the working channel of an endoscope, the Balloon is simultaneously inflated and cooled with an inert cryogen (nitrous oxide) delivered from the handle that ablates the BE cells upon contact with the esophagus.
Sponsors
Pentax Medical
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Low- or high-grade non-nodular, previously untreated (treatment naïve) dysplastic BE, confirmed by histopathological analysis. If nodular BE or Intramuscosal Cancer (ImCA) is identified during patient screening, this may be treated with Endoscopic Mucosal Resection (EMR) ≥6 weeks prior to treatment under this protocol. If previous EMR was performed, follow-up endoscopy must be negative for nodular BE. Patients with ImCA must be at low risk for recurrence, confirmed by EMR pathology results negative for positive margin, poorly differentiated carcinoma, and lymphovascular invasion. * BE length ≤6cm excluding visible BE islands, and Prague Classification C ≥0 / M ≥1 * Older than 18 years of age at time of consent * Operable per institution's standards * Provides written informed consent on the approved informed consent form * Willing and able to comply with study requirements for follow-up
Exclusion criteria
* Non-dysplastic or indefinite for dysplasia BE, confirmed by histopathological analysis * Esophageal stenosis/stricture preventing advancement of a therapeutic endoscope (patients may have the stenosis/stricture dilated and then be treated with CryoBalloon ablation under this protocol at a subsequent procedure ≥2 weeks later) * Symptomatic untreated strictures * Any endoscopically-visualized abnormalities such as ulcers, masses or nodules. Neoplastic nodules must first be treated with EMR ≥6 weeks prior to planned treatment under this protocol. * History of esophageal cancer more extensive than T1a or not meeting criteria for low risk of recurrence (confirmed by EMR pathology results negative for positive margin, poorly differentiated carcinoma, and lymphovascular invasion) * History of esophageal varices * Large (\>4cm) hiatal hernia * Prior distal esophagectomy * Any clinical or histological suspicion of esophageal adenocarcinoma invading into the submucosa by endoscopic mucosal resection (EMR), or confirmed T1a cancer with positive deep margin by EMR * Active esophagitis grade B or higher * Severe medical comorbidities precluding endoscopy * Uncontrolled coagulopathy * Pregnant or planning to become pregnant during period of study participation * Patient refuses or is unable to provide written informed consent * Life expectancy ≤3 years, as judged by the site investigator * General poor health, multiple co-morbidities placing the patient at risk or otherwise unsuitable for trial participation
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of serious, CryoBalloon Ablation System-related adverse events | 12 months |
| Percentage of patients with baseline LGD who have complete eradication of all dysplasia | 12 months |
| percentage of patients with baseline HGD who have complete eradication of all dysplasia | 12 months |
| percentage of all treated patients who have complete eradication of all dysplasia (CE-D) | 12 months |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of all treatment-related and all serious, non-treatment-related adverse events | 12 months | — |
| Incidence of post procedure chest discomfort events / Pain score >0 and <5 | Day 1 | (scored on a 0-10 visual analog pain scale) |
| Mean and Median Pain score on Day 1 post procedure | Day 1 | (scored on a 0-10 visual analog pain scale) |
| Rate of (CE-D) and all esophageal (CE-IM) will be reported as a percentage of all subjects enrolled, and stratified by baseline dysplasia grade | 24 and 36 months | — |
| Number of CryoBalloon ablation treatments required to achieve CE-D or CE-IM | 12 months | (mean and median) |
| Incidence of post procedure chest discomfort events / Pain score ≥5 and requiring narcotic analgesic | Day 7 | (scored on a 0-10 visual analog pain scale) |
| Mean and Median Pain score on Day 7 post procedure | Day 7 | (scored on a 0-10 visual analog pain scale) |
| Percentage of subjects with complete eradication of all esophageal intestinal metaplasia (CE-IM) | 12 months | — |
| Percentage of subjects with progression of dysplasia from LGD to HGD or esophageal cancer, or progression of HGD to cancer | 12 months | For Baseline LGD and HGD subjects: progression of dysplasia |
Countries
United States
Outcome results
None listed